Drug intelligence / Profile preview

GFS101A + toripalimab

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

GFS101A + toripalimab is an investigational combination therapy being studied for advanced solid tumors. GFS101A is a novel small molecule and toripalimab is a monoclonal antibody checkpoint inhibitor targeting programmed death protein 1 (PD-1). The combination aims to enhance antitumor immunity by simultaneously blocking immune-suppressive mechanisms and activating T-cell responses. Clinical trials are underway to evaluate the safety, pharmacokinetics, and potential efficacy for patients with advanced solid tumors, including metastatic or recurrent nasopharyngeal carcinoma.

Other names: GFS101A + toripalimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GFS101A + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GFS101A + toripalimab.

Explore the full profile